AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
0 hedge funds and large institutions have $0 invested in AVEO Pharmaceuticals, Inc. in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 110 closing their positions.
70.71% less ownership
Funds ownership: 70.71% → 0% (-71%)
100% less funds holding
Funds holding: 110 → 0 (-110)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $368M
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 110
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$22.6M |
| 2 |
Nexpoint Asset Management
Dallas,
Texas
|
-$21.9M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$21.6M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$20.1M |
| 5 |
Man Group
London,
United Kingdom
|
-$19.4M |
AVEO Hedge Fund Activity: Q1 2023 in Review
0 of the 6,289 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q1 2023, worth a combined $0 — down 100% from $368M a quarter earlier.
Sellers outnumbered buyers: 110 funds closed out of AVEO and 0 opened new positions — a net loss of 110 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Vanguard Group, exiting entirely with an estimated $22.6M sold.
- 0 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q1 2023, down from 110 in Q4 2022.
- Funds reported $0 of AVEO Pharmaceuticals, Inc. stock for Q1 2023, down 100% quarter-over-quarter.
- 0 funds opened new AVEO Pharmaceuticals, Inc. positions in Q1 2023 and 110 closed out, a net change of -110 holders.
- The largest AVEO Pharmaceuticals, Inc. seller in Q1 2023 was Vanguard Group, an estimated $22.6M sold.
Based on aggregated 13F filings for Q1 2023.